Earnings Call · Q3 FY2021·2021-11-09

Q3 21EPS -17.24%·Rev n/aQ2 21EPS -64.52%·Rev n/aQ1 21EPS -25.00%·Rev n/aQ4 20EPS -50.00%·Rev n/a⚠ consensus missing

Akebia Therapeutics, Inc. AKBA

Mercedes Carrasco — Investor Relations

John Butler — Chief Executive Officer

Dell Faulkingham — Chief Commercial Officer

Dave Spellman — Chief Commercial Officer

−9.0%1d on move date−9.5% vs SPY3d−14.1%5d−17.1%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more AKBA calls or request research access.

More AKBA calls Browse calls Request research access